JOHNSON & JOHNSON
JNJNYSEDrug Manufacturers - General • Healthcare
Comprehensive AI Analysis
Strategic AI Analysis for JNJ
Checking whether the approved providers contain enough current financial data for a reliable report.
Summary
Multi-agent institutional research for JNJ
Factor scores will populate once the financial statement data finishes loading.
Price Chart
NYSE:JNJ via TradingView
Loading TradingView chart...
Overview
Quarterly income statement data isn't available from current approved sources.
No Data
No annual financial data available.
Analyst Consensus
0 AnalystsCoverage count comes from 0 analyst opinions, but the Buy/Hold/Sell mix was not included in the current payload.
Price Target
Peer Comparison
| Ticker | Price | Mkt Cap | EV/EBITDA | Fwd P/E | Rev Growth | Gross Margin | FCF Yield |
|---|---|---|---|---|---|---|---|
JNJJOHNSON & JOHNSON | $253.85 | $611.1B | — | — | — | — | — |
Company News & Profile
Loading latest news...
About the Company
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Next Earnings Date
Jul 15, 2026